SLC7A11 and cancer: Despite these pharmacological dichotomies, which induce different types of death even when the target is the same, or which have differential action mechanisms in response to treatment with SAS, erastin (IKE) or HG106, the message that remains the same: SLC7A11 is a potent therapeutic target for cancer (Figure 2B).